Clinical outcomes, resource use, and costs at 1 year in patients with acute coronary syndrome undergoing PCI: Results from the multinational APTOR registry

Journal of Interventional Cardiology

Volumn 25, Issue 1, 2012, Pages 19-27

  Bakhai, Ameet ^a,b   Ferrieres, Jean ^c   Iñiguez, Andres ^d   Sartral, Magali ^e   Belger, Mark ^e   Schmitt, Claude ^e   Zeymer, Uwe ^f  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b AMORE Health Ltd   (United Kingdom)

^c CHU RANGUEIL   (France)

^d HOSPITAL DO MEIXOEIRO   (Spain)

^e ELI LILLY AND COMPANY   (United States)

^f Institut fur Herzinfarktforschung   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ADULT; ARTICLE; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; UNSTABLE ANGINA PECTORIS;

EID: 84857641038     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2011.00690.x     Document Type: Article

References (37)

1. Taylor MJ, Scuffham PA, McCollam PL, et al,. Acute coronary syndromes in Europe: 1-year costs and outcomes. Curr Med Res Opin 2007; 23: 495-503. (Pubitemid 46456897)
2. Anderson JL, Adams CD, Antman EM, et al., ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116: e148-e304.
3. Antman EM, Hand M, Armstrong PW, et al,. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008; 117: 296-329.
4. Bassand JP, Hamm CW, Ardissino D, et al,. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.
5. Van de Werf F, Bax J, Betriu A, et al,. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
6. Wijns W, Kolh P, Danchin N, et al,. Guidelines on myocardial revascularization: The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-2555.
7. Mahoney EM, Wang K, Arnold SV, et al,. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: Results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010; 121: 71-79.
8. Schwartz GG, Olsson AG, Ezekowitz MD, et al,. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-1718. (Pubitemid 32259905)
9. Mahoney EM, Mehta S, Yuan Y, et al,. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J 2006; 151: 219-227. (Pubitemid 41815359)
10. McCollam P, Etemad L,. Cost of care for new-onset acute coronary syndrome patients who undergo coronary revascularization. J Invasive Cardiol 2005; 17: 307-311. (Pubitemid 41724828)
11. Berenson K, Ogbonnaya A, Casciano R, et al,. Economic consequences of ACS-related rehospitalizations in the US. Curr Med Res Opin 2010; 26: 329-336.
12. Bufe A, Emile F, Drogoul L, et al,. Costs of bleeds relating to acute coronary syndrome therapies. J Med Econ 2010; 13: 236-240.
13. Menzin J, Wygant G, Hauch O, et al,. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin 2008; 24: 461-468. (Pubitemid 351294395)
14. Ferrieres J, Bakhai A, Iniguez A, et al,. Treatment patterns in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Curr Med Res Opin 2010; 26: 2193-2202.
15. National Institute for Health and Clinical Excellence (NICE). Unstable angina and NSTEMI: The early management of unstable angina and non-ST-segment-elevation myocardial infarction.; 2010.
16. British National Formulary: BNF 59 2010.
17. Department of Health. NHS Reference Costs 2008-2009. January 2010.
18. Curtis L., Unit Costs of Health and Social Care 2009. University of Kent, 2009.
19. BOT database of pharmaceutical prices. General Spanish Council of Pharmacists, 2010.
20. National Tariff Nomenclature. Ministry of Health, Madrid, 2010.
21. Non-official health cost database: Hospitalization and HCP visits. Ministerio de Sanidad, Madrid, 2010.
22. Brooks R,. EuroQol: The current state of play. Health Policy 1996; 37: 53-72. (Pubitemid 26191458)
23. Wiviott SD, Braunwald E, McCabe CH, et al,. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. (Pubitemid 350106708)
24. Wallentin L, Becker RC, Budaj A, et al,. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
25. Morrow DA, Wiviott SD, White HD, et al,. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: An application of the classification system from the universal definition of myocardial infarction. Circulation 2009; 119: 2758-2764.
26. Stone J, Hoffman GJ,. Medicare hospital readmissions: Issues, policy options and PPACA. Congressional Research Service, Washington, D.C., 2010.
27. Department of Health. The operating framework for the NHS in England 2010/11: National Health Service; 2010. Report No.: 299522, London.
28. Granger CB, Goldberg RJ, Dabbous O, et al,. Predictors of hospital mortality in the global registry of acute coronary events. Arch Inter Med 2003; 163: 2345-2353. (Pubitemid 37310196)
29. Eagle KA, Lim MJ, Dabbous OH, et al,. A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004; 291: 2727-2733. (Pubitemid 38725422)
30. Antman EM, Cohen M, Bernink PJ, et al,. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-842. (Pubitemid 30643610)
31. Morrow DA, Antman EM, Charlesworth A, et al,. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102: 2031-2037.
32. Brieger D, Fox KA, Fitzgerald G, et al,. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: The Global Registry of Acute Coronary Events. Heart (British Cardiac Society) 2009; 95: 888-894.
33. Mead A, Atkinson G, Albin D, et al,. Dietetic guidelines on food and nutrition in the secondary prevention of cardiovascular disease-Evidence from systematic reviews of randomized controlled trials (second update, January 2006). J Hum Nutr Diet 2006; 19: 401-419. (Pubitemid 44741532)
34. Taylor RS, Brown A, Ebrahim S, et al,. Exercise-based rehabilitation for patients with coronary heart disease: Systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116: 682-692. (Pubitemid 38581114)
35. Bakhai A, Ferrieres J, Iniguez A, et al,. International data on supportive therapies at 1 year in acute coronary syndrome patients undergoing PCI: results from the APTOR study. Eur J Cardiovasc Prev Rehabil 2011 Feb 18 [epub ahead of print].
36. Mehran R, Pocock SJ, Nikolsky E, et al,. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol; 55: 2556-2566.
37. Wiviott SD, Antman EM, Braunwald E,. Prasugrel. Circulation; 122: 394-403.